Advanced Filters
noise

Semaglutide Clinical Trials

A listing of Semaglutide medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 63 clinical trials
A Audrey Fish, BA

Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder

This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating moderate to severe alcohol use disorder (AUD) in Veterans. Participants who qualify will be randomly assigned to receive either semaglutide injections or placebo injections over a 28-week period, followed by a 4-week …

18 - 80 years of age All Phase 3
A Andrea Debs, MS

Imaging in Semaglutide Study

In this preliminary observation study, the investigators will assess muscle function in terms of muscle strength and leverage imaging (MRI) and spectroscopy (31P-MRS) based techniques to assess longitudinal changes in muscle volume, quality and metabolic function in patients with T2D and obesity prescribed to semaglutide therapy. The patients will be …

45 - 75 years of age All Phase N/A
C Caroline K Kramer, MD PhD

Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination

Semaglutide is a medication from the class of drugs called glucagon-like peptide-1 agonists that promote weight loss. There is little clinical data on the best strategy to achieve weight maintenance following weight reduction induced by semaglutide. For people who need to discontinue treatment, it is unknown whether the weight regain, …

18 - 75 years of age All Phase 3
A Apurva Raje

Feasibility of Semaglutide in Advanced Lung Disease

The goal of this clinical trial is to learn whether semaglutide, an FDA-approved treatment for diabetes and obesity, is feasible and tolerable in patients with advanced lung disease. The main question\[s\] it aims to answer are: Are patients with advanced lung disease able to tolerate semaglutide therapy? Are we able …

18 - 80 years of age All Phase 1/2
I Ida Voss, MD

Semaglutide Treatment for Hyperglycaemia After Renal Transplantation

Background: Post-transplant hyperglycaemia occurs frequently in renal transplant recipients within the first two weeks after transplantation. Standard-of-care is primarily based on insulin treatment with the adherent risk of hypoglycaemia and weight gain. Semaglutide produces an effective lowering of plasma glucose in diabetes patients with chronic kidney disease (CKD) and leads …

18 - 80 years of age All Phase 4
J Jessica Vincent, MD

Semaglutide for Post-Smoking Cessation Weight Management

This trial will examine the effect of semaglutide 2.4mg on changes in body weight, body composition, and peripheral and central mechanisms that control appetite, satiety, and food intake in the context of smoking cessation.

18 - 75 years of age All Phase 2
N Nidhi Agarwal

Semaglutide for Smoking Cessation in Patients With Diabetes

To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

18 years of age All Phase 3
B Bri Hihara

Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes

This trial plans to learn more about the effects of a medication, semaglutide, on cardiovascular function, kidney function, and insulin sensitivity in adults with type 1 diabetes. This medication has been effective in reducing cardiovascular disease and diabetic kidney disease and improving glucose control and BMI in adults with type …

18 - 49 years of age All Phase 3
A Alireza Faridar

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited. Growing evidence suggests that inflammation in the brain and the body plays a key role in the onset and progression of AD. In particular, immune cells …

50 - 86 years of age All Phase 1/2
J Jessica Vincent, MD

Repurposing Semaglutide for the Treatment of Cocaine Use Disorder

The purpose of this study is to evaluate semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), in combination with cognitive behavioral therapy (CBT) for the treatment of cocaine use disorder (CUD). This project is part of the NIH Helping to End Addiction Long-term (HEAL) initiative (https://heal.nih.gov/).

18 years of age All Phase 2

Simplify language using AI